Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18131267 | 0.90 | CA12 (0.45) | CA12CA1CA2CA9CTSB | |
| SCHEMBL28329225 | 0.87 | CA12 (0.47) | CA12CA1CA2CA9CTSB | |
| SCHEMBL23390494 | 0.87 | CA12 (0.42) | CA12CA1CA2CA9CTSB | |
| SCHEMBL17322491 | 0.86 | ALDH1A1 (0.48) | CA1CA2ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL20480629 | 0.86 | ALDH1A1 (0.43) | CA12CA1CA2CA9CTSB | |
| SCHEMBL28328057 | 0.84 | LMNA (0.48) | CA12CA1CA2CA9CTSB | |
| SCHEMBL29420342 | 0.84 | CTSL (0.50) | CA12CA1CA2CA9CTSB | |
| SCHEMBL28329266 | 0.83 | CA1 (0.48) | CA1CA2CTSBCTSSCTSL | |
| SCHEMBL31443319 | 0.82 | CA1 (0.45) | CA12CA1CA2CA9CTSB | |
| SCHEMBL5122730 | 0.82 | CA12 (0.51) | CA12CA1CA2CA9CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483392-A | Synthesize the method and synthetic intermediate of the quinoline -7- base oxygroup methylcyclopropyl groups amine derivative of N-protected | SERVIER LAB | 2019-11-22 | — | — | CN | claimed |
| EP-3291814-B1 | AN ANTI-CANCER AGENT 1-((4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)METHYL) CYCLOPROPANAMINE, ITS CRYSTALLINE FORM AND ITS SALTS | ADVENCHEN PHARMACEUTICALS LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2020020190-A1 | METHOD FOR SYNTHESIZING QUINOLINE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
| US-10544125-B2 | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts | Advenchen Pharmaceuticals, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544125-B2 | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts | Advenchen Pharmaceuticals, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| CN-110483392-A | Synthesize the method and synthetic intermediate of the quinoline -7- base oxygroup methylcyclopropyl groups amine derivative of N-protected | SERVIER LAB | 2019-11-22 | — | — | CN | disclosed |
| US-20190002435-A1 | PROCESS FOR PREPARING AN ANTI-CANCER AGENT, 1-((4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)METHYL)CYCLOPROPANAMINE, ITS CRYSTALLINE FORM AND ITS SALTS | Advenchen Pharmaceuticals, LLC | 2019-01-03 | — | — | US | disclosed |
| US-20190002435-A1 | PROCESS FOR PREPARING AN ANTI-CANCER AGENT, 1-((4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)METHYL)CYCLOPROPANAMINE, ITS CRYSTALLINE FORM AND ITS SALTS | Advenchen Pharmaceuticals, LLC | 2019-01-03 | — | — | US | disclosed |
| US-10100034-B2 | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts | Advenchen Pharmaceuticals, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3291814-A1 | PROCESS FOR PREPARING AN ANTI-CANCER AGENT, 1-((4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)METHYL) CYCLOPROPANAMINE, ITS CRYSTALLINE FORM AND ITS SALTS | Advenchen Pharmaceuticals LLC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8148532-B2 | Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases | CHEN GUOQING PAUL (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2012-01-12 | — | — | US | disclosed |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2012-01-12 | — | — | US | disclosed |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2012-01-12 | — | — | US | disclosed |
| WO-2010105761-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
| EP-2125776-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | Advenchen Laboratories, LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008112407-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544125-B2 | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts | ACTR8, UACA, API5 | CA12 1489/4885CA1 2194/4885CA2 1163/4885 |
| US-20190002435-A1 | PROCESS FOR PREPARING AN ANTI-CANCER AGENT, 1-((4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)METHYL)CYCLOPROPANAMINE, ITS CRYSTALLINE FORM AND ITS SALTS | ACTR8, UACA, API5 | CA12 1489/4885CA1 2194/4885CA2 1163/4885 |
| US-10100034-B2 | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts | ACTR8, CDK18, UACA | CA12 1205/4885CA1 1768/4885CA2 1084/4885 |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | CA12 2199/4885CA1 2236/4885CA2 1161/4885 |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | CA12 2199/4885CA1 2236/4885CA2 1161/4885 |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CYP2B6, CYP2A6, NAT1 | CA12 2964/4885CA1 3579/4885CA2 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.